

BLL/SECT/07/2023-24**Date: 9 February 2024**

To,
The Secretary,
National Stock Exchange of India Ltd.,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051

NSE Symbol: BANKA

Dear Sir/Madam,

Sub: Outcome of Board Meeting dated 9 February 2024.

This is to inform you that the Board of Directors at its Meeting held today, i.e., 9 February 2024 has inter alia –

1. Based on the recommendation of the Audit Committee, considered and approved the Unaudited standalone and consolidated financial results of the Company for the quarter and nine months ended 31 December 2023.

A copy of the aforementioned Financial Results along with the Auditors' Limited Review Report thereon pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") is enclosed herewith.

We are also arranging to upload the aforesaid Financial Results on the Company's Website www.bankabio.com and shall publish the Financial Results in the newspapers, in the format prescribed under Regulation 47 of the SEBI Listing Regulations.

2. Pursuant to the Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and based on the recommendation of Nomination and Remuneration Committee of the Company, the Board of Directors has approved the appointment of Ms. Naina Singh as the Company Secretary and Compliance Officer of the Company w.e.f. 9 February 2024.

Pursuant to SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, a brief profile of Ms. Naina Singh is given hereunder.

| | |
|--|--|
| Name of KMP | Ms. Naina Singh |
| Designation | Company Secretary and Compliance Officer |
| Date of Birth | June 14, 1993 |
| Reason of change viz. appointment, resignation, removal, death or otherwise | Appointment |
| Brief profile | Ms. Naina Singh is an Associate member of the Institute of Company Secretaries of India. She has 2 years of experience in corporate laws and SEBI compliances. |
| Disclosure of relationship between directors (In case of appointment of a director) | Not Applicable |

The meeting commenced at 2:00 PM and concluded at 4:00 PM.

We request you to kindly take note of the same in your record.

Thanking you,

For Banka BioLoo Limited

Namita Banka
Managing Director
DIN: 5017358

Encl: As above



Independent Auditor's Review Report on the Unaudited Standalone Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


To The Board of Directors of BANKA BIOLOO LIMITED

1. We have reviewed the accompanying Statement of unaudited standalone financial results of **BANKA BIOLOO LIMITED** for the quarter and nine months ended December 31, 2023 ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
2. This Statement, which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India, read with the circular, is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free from material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

For PRSV & Co.LLP


Chartered Accountants

Firm Registration No: S200016


M.Srichanakya

Partner

Membership No: 219339



Place: Hyderabad

Date: 09-02-2024

UDIN: 24219339BKETUZ9016

BANKA BIOLOO LIMITED

Unaudited STANDALONE Statement of Financial Results for the Quarter and Nine Months ended 31 December 2023

Rs. In Lacs

| S. No | Particulars | Quarter Ended | | | Nine Months Ended | | Year Ended |
|-------|---|------------------|------------------|------------------|-------------------|------------------|----------------|
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| | | 31.12.2023 | 30.09.2023 | 31.12.2022 | 31.12.2023 | 31.12.2022 | 31.03.2023 |
| 1 | Income | | | | | | |
| | Revenue from Operations | 1474.87 | 1055.42 | 1048.88 | 3341.12 | 3014.18 | 4214.32 |
| | Other income | 19.38 | 16.97 | 15.14 | 57.53 | 40.18 | 81.24 |
| | Total Income | 1494.25 | 1072.39 | 1064.02 | 3398.65 | 3054.37 | 4295.56 |
| 2 | Expenses | | | | | | |
| | Cost of materials consumed | 347.30 | 189.48 | 159.36 | 829.44 | 432.88 | 787.29 |
| | Changes in inventories of finished goods & work-in-progress | 125.51 | (11.02) | (7.94) | 158.28 | (33.66) | (29.71) |
| | Employee benefits expense | 670.95 | 544.54 | 560.68 | 1729.92 | 1685.93 | 2245.29 |
| | Finance costs | 51.78 | 50.99 | 42.21 | 143.74 | 120.99 | 133.16 |
| | Depreciation and amortisation expense | 42.84 | 42.27 | 27.56 | 126.96 | 87.10 | 143.38 |
| | Other expenses | 147.44 | 153.15 | 97.66 | 384.39 | 446.40 | 601.38 |
| | Total expenses | 1385.81 | 969.41 | 879.53 | 3372.73 | 2739.64 | 3880.78 |
| 3 | Profit/(loss) before tax | 108.44 | 102.98 | 184.49 | 25.92 | 314.73 | 414.78 |
| 4 | Tax expense | | | | | | |
| | (1) Current tax | - | 2.75 | 42.50 | 2.75 | 58.05 | 55.41 |
| | (2) Taxes for earlier years | - | - | - | - | - | 24.98 |
| | (3) MAT Credit | - | - | - | - | - | - |
| | (4) Deferred tax | - | (5.44) | 12.09 | (7.19) | (7.43) | 26.75 |
| | Total Tax expense | - | (2.69) | 54.59 | (4.44) | 50.63 | 107.14 |
| 5 | Profit after tax | 108.44 | 105.67 | 129.90 | 30.36 | 264.10 | 307.64 |
| | Other comprehensive income | | | | | | |
| | <i>Items that will not be reclassified to profit and loss</i> | | | | | | |
| | Remeasurement of post-employment benefit obligations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.76 |
| | Income tax effect on items that will not be reclassified | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.95) |
| | Other comprehensive income for the year | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.81 |
| | Total comprehensive income for the year | 108.44 | 105.67 | 129.90 | 30.36 | 264.10 | 313.44 |
| 6 | Paid up equity share capital (Face value Rs. 10/- each) | 1084.66 | 1084.66 | 1084.66 | 1084.66 | 1084.66 | 1084.66 |
| 7 | Earnings per share | | | | | | |
| | Basic and Diluted Earnings per share (in Rs.) | 1.00 | 0.97 | 1.20 | 0.28 | 2.43 | 2.84 |
| | | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | (Annualised) |

FOR & ON BEHALF OF BOARD OF DIRECTORS

Place: Hyderabad

Date: 09.02.2024


 Vishal Murarka
 CEO & Executive Director
 DIN: 06729485



Notes:

1. The above unaudited Standalone Financial Result was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on February 9, 2024.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter and nine months ended December 31, 2023 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended March 31, 2023.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka BioLoo Limited

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 9 February 2024




Independent Auditor's Review Report on Review of Consolidated Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To The Board of Directors of BANKA BIOLOO LIMITED

1. We have reviewed the accompanying Statement of Consolidated unaudited financial results of **BANKA BIOLOO LIMITED** ("the Parent") its Subsidiaries (the Parent and Subsidiaries together referred to as "the Group") and its share of the net profit/(loss) after tax and total comprehensive income / loss of its associate for the quarter ended December 31, 2023 and for the period from April 1, 2023 to December 31, 2023 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



4. The Statement includes the results of the following entities.

Holding Company

BANKA BIOLOO LIMITED

Subsidiaries


1. ENZOTECH SOLUTIONS PRIVATE LIMITED – Wholly Owned Subsidiary
2. MEGALITER VARUNAA PRIVATE LIMITED

Associate

SAI BANKA SPV PRIVATE LIMITED

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with rule 7 of the Companies (Accounts) Rules, 2014 and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of one wholly owned subsidiary included in the consolidated unaudited financial results, whose total revenues of Rs. 90.76 Lacs and Rs. 212.86 Lacs, total net loss of Rs.11.00 Lacs and Rs.69.89 Lacs and total comprehensive loss of Rs.11.00 Lacs and Rs. 69.89 Lacs for the quarter ended December 31, 2023, and for the period from April 1, 2023, to December 31, 2023, respectively, as considered in the consolidated unaudited financial results. These interim financial statements / financial information / financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the wholly owned subsidiary is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.
7. We did not review the interim financial information of one subsidiary included in the unaudited consolidated financial results, which have not been reviewed by their auditor, whose total revenues of Rs. 50.83 Lacs and Rs.183.22 Lacs, total net loss after tax of Rs.22.03 Lacs and net profit of Rs.0.15 Lacs and total comprehensive loss of Rs. 22.03 lacs and total comprehensive profit of Rs.0.15 Lacs for the quarter ended December 31, 2023, and for the period from April 1, 2023, to December 31, 2023, respectively as the consolidated unaudited financial results.
- The statement also includes financial results of one associate as mentioned above, whose share of net profit after tax of Rs. 0.10 Lacs and Rs.1.46 Lacs and total comprehensive income of Rs. 0.10 Lacs and Rs.1.46 Lacs for the quarter ended December 31, 2023 and for the period from April 1, 2023 to December

me




31, 2023, respectively, as considered in the unaudited consolidated financial results, based on their interim financial results which have not been reviewed by the auditors and which has been furnished to us by the Management and these unaudited interim standalone financial results are not material to the group.


Our conclusion on the Statement is not modified in respect of the above matter.

For PRSV & Co. LLP

Chartered Accountants

Firm Registration No: S200016


M. Srichanakya
Partner
Membership No: 219339



Place: Hyderabad

Date: 09-02-2024

UDIN: 24219339BKETVA5309

BANKA BIOLOO LIMITED

Unaudited CONSOLIDATED Statement of Financial Results for the Quarter & Nine months ended 31.12.2023

Rs. In lacs

| S. No | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|-------|---|------------------|------------------|------------------|-------------------|------------------|-----------------|
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| | | 31.12.2023 | 30.09.2023 | 31.12.2022 | 31.12.2023 | 31.12.2022 | 31.03.2023 |
| 1 | Income | | | | | | |
| | Revenue from Operations | 1395.68 | 1145.08 | 1070.68 | 3368.31 | 3416.70 | 4,234.98 |
| | Other income | 11.01 | 9.16 | 10.50 | 37.46 | 35.22 | 70.11 |
| | Total Income | 1406.69 | 1154.24 | 1081.18 | 3405.76 | 3451.92 | 4,305.09 |
| 2 | Expenses | | | | | | |
| | Cost of materials consumed | 228.94 | 211.50 | 137.69 | 733.51 | 647.50 | 593.21 |
| | Changes in inventories of finished goods & work-in-progress | 122.41 | (10.44) | (4.38) | 169.73 | (42.81) | (39.35) |
| | Employee benefits expense | 677.78 | 555.68 | 588.04 | 1763.14 | 1781.96 | 2,370.09 |
| | Finance costs | 65.21 | 68.01 | 47.01 | 184.01 | 137.19 | 154.81 |
| | Depreciation and amortisation expense | 56.50 | 55.03 | 28.66 | 157.46 | 90.57 | 148.25 |
| | Other expenses | 188.62 | 158.95 | 127.24 | 446.31 | 541.76 | 716.31 |
| | Total expenses | 1339.46 | 1038.73 | 924.27 | 3454.17 | 3156.18 | 3,943.32 |
| 3 | Share of profit/(loss) of Associates | 0.10 | 0.53 | 4.17 | 1.47 | 7.34 | 0.64 |
| 4 | Profit/(loss) before tax | 67.33 | 116.04 | 161.08 | (46.94) | 303.08 | 362.41 |
| 5 | Tax expense | | | | | | |
| | (1) Current tax | 0.00 | (2.13) | 40.34 | 2.75 | 58.05 | 56.88 |
| | (2) Taxes for earlier years | 0.00 | - | 0.00 | 0.00 | 0.00 | 24.98 |
| | (3) MAT Credit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| | (4) Deferred tax | (1.71) | (3.77) | 12.11 | (7.26) | (7.42) | 26.65 |
| | Total Tax expense | (1.71) | (5.90) | 52.44 | (4.51) | 50.63 | 108.51 |
| 6 | Profit after tax | 69.03 | 121.94 | 108.64 | (42.43) | 252.45 | 253.89 |
| | Other comprehensive income | | | | | | |
| | <i>Items that will not be reclassified to profit and loss</i> | | | | | | |
| | Remeasurement of post-employment benefit obligations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.76 |
| | Income tax effect on items that will not be reclassified | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.95) |
| | Other comprehensive income for the year | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.81 |
| | Total comprehensive income for the year | 69.03 | 121.94 | 108.64 | (42.43) | 252.45 | 259.70 |
| | Attributable to | | | | | | |
| | Shareholders of the Company | 70.13 | 121.94 | 108.64 | (41.47) | 252.45 | 259.70 |
| | Non controlling interest | (1.10) | 0.14 | 0.00 | (0.96) | 0.00 | - |
| 7 | Paid up equity share capital (Face value Rs. 10/- each) | 1084.66 | 1084.66 | 1084.66 | 1084.66 | 1084.66 | 1,084.66 |
| 8 | Earnings per share | | | | | | |
| | Basic and Diluted Earnings per share (in Rs.) | 0.65 | 1.12 | 1.00 | (0.38) | 2.33 | 2.39 |
| | | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | (Not annualised) | (Annualised) |

FOR & ON BEHALF OF BOARD OF DIRECTORS

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 09.02.2024

Notes:

1. The above statement of unaudited Consolidated Financial Result was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on February 9, 2024.
2. The Consolidated Financial Results have been prepared in accordance with Indian Accounting Standards ("INDAS") prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under and other accounting principles generally accepted in India and the guidelines issued by SEBI.
3. The consolidated financial results of the Group include the results of the Company and results of the following entities.

| Name of the entity | Status |
|----------------------------|-------------------------|
| Enzotech Solutions Pvt Ltd | Wholly owned subsidiary |
| Megaliter Varunaa Pvt Ltd | Subsidiary |
| Sai Banka SPV Pvt Ltd | Associate |

4. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
5. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
6. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka BioLoo Limited

Vishal Murarka

Vishal Murarka
CEO & Executive Director
DIN: 06729485



Place: Hyderabad
Date: 9 February 2024